Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company ...

Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a ...

RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in ...

Praxis Precision Medicines' vormatrigine shows promise in epilepsy with 56.3% seizure reduction. Click here to find out why I ...

Praxis Precision Medicines’ oral vormatrigine stopped 100% of seizures in 22% of patients in a Phase II trial. The RADIANT ...

Praxis’ vormatrigine reduced seizures by 56.3%, an effect size that, according to analysts at Truist Securities, exceeds that ...

Positive results from a mid-stage study apparently weren’t enough to raise investor confidence in Praxis Precision Medicines ...

Investing.com -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) stock surged 27% on Monday after the company announced positive topline results from its Phase 2 RADIANT study evaluating vormatrigine ...

Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) soared 27% on Monday after the company released encouraging top-line ...

Key Points Earnings per share (GAAP) was ($3.31) in Q2 2025, wider than the ($3.25) GAAP loss analysts expected, with source data indicating an actual GAAP EPS of ($3.39). Praxis did not recognize any ...

Praxis Precision Medicines Inc (PRAX) extends cash runway into 2028 while reporting significant seizure reduction and ...

In other recent news, Praxis Precision Medicines has been granted Breakthrough Therapy Designation by the FDA for its drug relutrigine, intended to treat SCN2A and SCN8A developmental and ...